BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36646712)

  • 1. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
    Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
    Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
    Motomura K; Kibe Y; Ohka F; Aoki K; Yamaguchi J; Saito R
    Brain Tumor Pathol; 2023 Apr; 40(2):48-55. PubMed ID: 36988764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
    Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
    Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
    Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
    Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
    Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
    Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
    J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
    Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
    Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
    Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Berzero G; Di Stefano AL; Ronchi S; Bielle F; Villa C; Guillerm E; Capelle L; Mathon B; Laurenge A; Giry M; Schmitt Y; Marie Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M
    Neuro Oncol; 2021 Jun; 23(6):955-966. PubMed ID: 33173941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the occurrence rates of
    Cho U; Yang SH; Yoo C
    J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
    Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
    Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
    Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
    Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.